Which adjunct therapy is used in pediatric diabetic ketoacidosis to reduce the risk of cerebral edema?

Which adjunct therapy is used in pediatric diabetic ketoacidosis to reduce the risk of cerebral edema?

• A. Furosemide
• B. Hypertonic saline
• C. Mannitol
• D. Vitamin K

Answer: (C)

Cerebral edema is a serious concern during pediatric DKA treatment, and lowering intracranial pressure can help prevent its progression. Mannitol works as an osmotic agent: when given IV, it raises the blood’s osmolality, pulling water out of swollen brain tissue and into the vascular space. This osmotic gradient reduces brain water content and lowers intracranial pressure, which is why it’s used as an adjunct therapy to lessen the risk of cerebral edema in this setting. The other options don’t fit as well. Furosemide is a diuretic and doesn’t address brain swelling; it can worsen dehydration and electrolyte imbalances. Hypertonic saline can treat established cerebral edema but isn’t the default prophylactic choice in this context. Vitamin K has no role in managing DKA-related cerebral edema.

Cerebral edema is a serious concern during pediatric DKA treatment, and lowering intracranial pressure can help prevent its progression. Mannitol works as an osmotic agent: when given IV, it raises the blood’s osmolality, pulling water out of swollen brain tissue and into the vascular space. This osmotic gradient reduces brain water content and lowers intracranial pressure, which is why it’s used as an adjunct therapy to lessen the risk of cerebral edema in this setting.

The other options don’t fit as well. Furosemide is a diuretic and doesn’t address brain swelling; it can worsen dehydration and electrolyte imbalances. Hypertonic saline can treat established cerebral edema but isn’t the default prophylactic choice in this context. Vitamin K has no role in managing DKA-related cerebral edema.